An efficient expression system in Escherichia coli for several biologically active insulin-like growth factor-I (IGF-I) fusion peptide analogues is described. 
binds to the type-2 receptor, the functions of which are yet to be established (Humbel, 1990 (Ballard, Francis, Ross et al. 1987; Bagley, May, Szabo et al. 1989 ; Wallace, Bagley, May et al. 1989 ). Furthermore, we established that the enhanced biological potency of these analogues arises from their reduced binding to IGFBPs se¬ creted into the medium by cells in culture Ross, Francis, Szabo et al. 1989) . Investi¬ gation of the mechanisms involved in IGF action would be facilitated by the availability of analogues with altered IGFBP-and receptor-binding proper¬ ties.
Recently, we described an efficient expression system in Escherichia coli for IGF-I analogues as fusion peptides (King, Wells, Krieg et al. 1992 ).
The expressed proteins have a 46 amino acid Nterminal extension derived from methionyl porcine growth hormone ([Met'j-pGH) (Vieira & Messing, 1982) (Messing, 1979) , by growth on minimal medium as described previously (King et al. 1992 (Fig. 2a) (Fig. 2a) . Purification of the major refolded species through ion-exchange chromatography and concentration on C18 silica produced 816 mg partially pure fusion peptide. Further purification through several re¬ verse-phase HPLC steps yielded 392 mg homo¬ geneous peptide (Fig. 26) (Fig. 3b) (Vize & Wells, 1987 (Thatcher, 1990; King et al. 1992 ). In the present report, the critical refolding step proceeds with almost quantitative yield (Fig. 2a) . This is in contrast with our previous experience of refolding either chemically synthesized or recombinantly produced IGF-I King et al. 1992 ) and that of others (Saito, Yamada, Niwa & Ueda, 1987; Raschdorf, Dahinden, Maerki et al. 1988 ). Samuelsson, Wadensten, Hartmanis et al. (1991) recently described the problems associated with the misfolding of recombinant IGF-I that also arise during production using a direct-secretion system. The latter approach employed a fusion protein to improve the solubility and recovery of incorrectly folded IGF-I for refolding. The Tomas, Knowles, Owens et al. 1991) .
The increased biological potency of the Long IGF analogues relative to authentic IGF-I in rat L6 myoblasts is not unexpected from our previous findings (Ballard et al. 1987; Francis et al. 1988; Bagley et al. 1989; King et al. 1992 (Mottola & Czech, 1984) . Our results here and previously (Gunn, Clark, Knowles et 
